NJ Primary Care

NJ Primary Care operates as a comprehensive primary care practice in Jersey City, New Jersey, integrating peptide-based weight management protocols with traditional family medicine services. The clinic prescribes tirzepatide and semaglutide—GLP-1 receptor agonists originally developed for type 2 diabetes management—as part of structured weight loss programs that include metabolic assessment, nutritional counseling, and ongoing monitoring. Patients receive individualized dosing schedules based on baseline labs, body composition analysis, and response to therapy, with providers adjusting treatment protocols to minimize gastrointestinal side effects while optimizing fat loss and glycemic control. The practice serves Jersey City residents seeking medically supervised weight reduction alongside routine primary care, offering both in-person visits at their Hudson County location and telehealth consultations for established patients across New Jersey.

The weight management program at NJ Primary Care begins with comprehensive metabolic screening, including fasting glucose, hemoglobin A1c, lipid panels, thyroid function tests, and liver enzymes to identify contraindications and establish baseline health markers. Tirzepatide, a dual GIP/GLP-1 receptor agonist, is prescribed for patients requiring more aggressive appetite suppression and weight reduction, while semaglutide serves patients with milder obesity or those transitioning from other therapies. The clinic provides weekly or biweekly injections depending on the peptide selected, with dosage escalation protocols that typically span 16-20 weeks to reach maintenance levels. Providers monitor patients for common adverse effects including nausea, constipation, and gallbladder complications, adjusting injection timing and dietary recommendations to improve tolerance. The practice does not offer compounded formulations, prescribing only FDA-approved branded medications through partnered pharmacies that coordinate delivery to patients' homes or local pickup locations in Jersey City.

NJ Primary Care's medical team includes board-certified physicians and nurse practitioners who manage the full spectrum of adult primary care, from hypertension and diabetes to sexual health concerns and gender-affirming care for LGBTQIA+ patients. Providers integrate peptide therapy into broader preventative care strategies, addressing sleep quality, stress management, and exercise capacity as part of weight loss treatment plans. The practice emphasizes disease management for patients with metabolic syndrome, using semaglutide and tirzepatide not only for weight reduction but also for cardiovascular risk mitigation and improved insulin sensitivity. Sexual health services include evaluation and treatment of erectile dysfunction, low libido, and hormone-related concerns, with providers assessing whether weight loss peptides may improve sexual function through metabolic improvements. The clinic also offers pre-travel consultations, vaccinations, and prophylactic medications for patients planning international trips, providing a medical home for Jersey City residents with diverse healthcare needs.

Patients initiating peptide therapy at NJ Primary Care attend an initial consultation—available in-person or via telehealth for New Jersey residents—where providers review medical history, current medications, and weight loss goals to determine candidacy for GLP-1 agonist therapy. The clinic requires baseline laboratory work before prescribing tirzepatide or semaglutide, typically completed at partnered labs in Hudson County or through at-home phlebotomy services. Follow-up visits occur monthly during the dose escalation phase, transitioning to quarterly appointments once patients reach stable maintenance dosing. Providers track weight, blood pressure, and subjective tolerance at each visit, ordering repeat metabolic panels every three to six months to monitor for hepatic or pancreatic complications. The practice does not require long-term contracts, allowing patients to discontinue therapy if side effects become intolerable or weight loss goals are achieved, though providers counsel on the high likelihood of weight regain after cessation and strategies for transitioning to lifestyle-based maintenance.

With a 4.1-star rating across 525 Google reviews, NJ Primary Care maintains an active patient base in Jersey City, though feedback reflects variability in appointment availability and wait times common to high-volume urban primary care practices. The clinic's hybrid model allows established patients to conduct routine follow-ups via telehealth, reducing the need for in-person visits while maintaining continuity of care for peptide therapy management. New patients seeking weight loss treatment must complete an initial in-person evaluation at the Jersey City office, after which telehealth becomes available for prescription refills and progress monitoring. The practice accepts most major insurance plans for primary care visits, though peptide medications themselves often require prior authorization or are paid out-of-pocket depending on coverage. NJ Primary Care provides cost estimates for self-pay patients and assists with insurance appeals for patients whose plans deny coverage for weight loss indications, positioning the clinic as an accessible option for Jersey City residents seeking medically supervised GLP-1 therapy within a full-service primary care setting.